E21R: BBG will begin this quarter an Australian Phase II trial in 13 patients of E21R to treat RA. The compound also is in Phase II testing for acute myeloid le

British Biotech plc (LSE:BBG; BBIOY), Oxford, U.K.
Product: E21R

Read the full 95 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE